Combining anti-cancer drugs has the potential to increase treatment efficacy. Because patient responses to drug combinations are highly variable, predictive biomarkers of synergy are required to identify which patients are likely to benefit from a drug combination. To aid biomarker identification, the DREAM challenge consortium has recently released data from a screen containing 85 cell lines and 167 drug combinations. The main challenge of these data is the low sample size: per drug combination, a median of 14 cell lines have been screened. We found that widely used methods in single drug response prediction, such as Elastic Net regression per drug, are not predictive in this setting. Instead, we propose to use multi-task learning: training a single model simultaneously on all drug combinations, which we show results in increased predictive performance. In contrast to other multi-task learning approaches, our approach allows for the identification of biomarkers, by using a modified random forest variable importance score, which we illustrate using artificial data and the DREAM challenge data. Notably, we find that mutations in MYO15A are associated with synergy between ALK / IGFR dual inhibitors and PI3K pathway inhibitors in triple-negative breast cancer.
Combining drugs is a promising strategy for cancer treatment, as drug combinations can tumor's DNA that are associated with a favorable response to the drug combination), 7 the selection of a given patient's treatment can be improved. To facilitate biomarker 8 identification, data from a large-scale drug combinations screen were recently released 9 as part of the AstraZeneca-Sanger DREAM challenge [14] , containing 85 cell lines with 10 their response to 167 drug combinations.
11
While the data from this screen can provide information on potential biomarkers of 12 synergy, it is not yet clear what is the best way to identify them. In the context of 13 single drug response prediction, the default approach is to fit 'individual models' that 14 are trained separately per drug. We applied a similar approach here in the context of 15 drug combinations, training 'individual models' for each drug combination separately 16 ( Fig 1A) . However, we show that such an approach is unsuitable for the dataset at hand 17 due to the extremely low sample size: a median number of 14 cell lines have been 18 screened per drug combination.
19
We propose to alleviate the problem of low sample size by training 'joint models' 20 that use information from all drug combinations simultaneously (Fig 1B) . In the 21 literature, this is known as multi-task learning [4, 15] . This approach has been employed 22 before in single drug response prediction by Gönen et al. (2014) [9] , Menden et al.
23
(2013) [13] and Yuan et al. (2016) [19] , and in synergy prediction by other participants 24 in the AstraZeneca-Sanger DREAM challenge [14] . What distinguishes our approach 25 from other multi-task learning approaches is that we are able to identify biomarkers, 26 whereas others have proposed black-box models. Specifically, the Joint Random Forest 27 model we propose is simultaneously trained on all drug combinations, after which we 28 apply our Drug-combination-specific Variable Importance (DVI) score to the trained 29 Joint Random Forest to identify biomarkers of synergy. We provide a Python 30 implementation on our Github (https://github.com/NKI-CCB/multitask_vi/).
31
We show that the joint model outperforms individual models in terms of predictive 32 performance. Using the joint model together with the DVI, we are able to identify 33 biomarkers of response on both simulated and real data. Finally, we found that 34 MYO15A mutations associate with synergy between an ALK / IGFR dual inhibitor and 35 PI3K pathway inhibitors in triple-negative breast cancer.
36

Results
37
The AstraZeneca-Sanger DREAM challenge data 38 In order to predict synergy from molecular data, we have used the data from the 39 AstraZeneca-Sanger DREAM challenge (from here on referred to as: DREAM data) [14] . 40 The goal of this community challenge was to create models that predict whether a given 41 drug combination will show synergy in certain cell lines. The DREAM data include 85 42 cell lines and 167 drug combinations, with a median of 14 cell lines screened per drug 43 combination. The dataset consists of three parts: synergy scores, monotherapy response 44 data and molecular data of the cell lines (e.g. mutations and copy number alteration 45 data).
46
As the response variable for our model, we used the synergy scores as provided in 47 the DREAM data, which were based on a Loewe additivity model [5, 8] . For each cell 48 line, drug combination pair, monotherapy data were available, quantifying the response 49 of a cell line to each individual drug in the drug combination by the 50% Inhibitory 50 Concentration (IC50) or the Area Under the dose-response Curve (AUC). For each cell 51 line, molecular data were provided in the form of mutation, copy number alteration 52 (CNA), methylation and gene expression data. Because of the high dimensionality and 53 the low sample size, we restricted mutations and CNAs to a reduced set of potential 54 driver genes. Finally, we defined 'pathway rules' that integrate the mutation and CNA 55 data with information from KEGG [11, 12] . More information on how these data were 56 processed is provided in the S1 Text.
57
We used the monotherapy and the molecular data of the cell lines to predict drug 58 synergy (Fig 1) . More formally, we defined the input matrix X using 382 mutation, 76 59 copy number, 23 monotherapy, and 16 pathway rule variables. The response vector y 60 was defined using the synergy scores. Each of the input data types explain a part of the 61 synergy and are therefore useful to include in a predictive model. For biomarker 62 identification we focused on genomic variables only, as monotherapy data are unlikely to 63 be useful as clinical biomarkers (this information is typically not available for most 64 drugs for a given patient).
65
Per-combination individual models perform poorly
66
For our initial approach, we used the DREAM data to create 'individual models' that 67 are trained separately per drug combination (Fig 1A) (Methods). To test the variability 68 across different prediction methods, the individual models were trained using either 69 Elastic Net, SVM (with RBF kernels) or Random Forest. For each method, predictive 70 performance was assessed using cross-validation with the 'primary score' (a weighted 71 average of the correlation between the observed and predicted synergy scores) defined in 72 the DREAM challenge [14] as endpoint.
73
Overall, the predictive performance of the individual models was low for all methods 74 (0.04 on average) (Fig 2A) , most likely due to the extremely low sample size (median of 75 14 cell lines per combination). We also observed that the predictions from the 76 individual SVM models resulted in negative correlations between the observed and 77 predicted synergy scores (Fig 2A) . This is due to a cross-validation artifact that leads to 78 negative correlations when the model is unable to detect structure in the data (S2 Text), 79 which likely mostly affected the SVM due to the high complexity of the RBF kernels.
80
Simultaneously learning across drug combinations improves 81 predictive performance
82
To alleviate the low sample size problem, we created 'joint models', which are trained on 83 all drug combinations simultaneously, thereby leveraging the information from the 84 entire dataset. Using cross-validation, we found that the joint models achieve higher 85 predictive performance compared to individual models (Fig 2A) , regardless of the 86 underlying method (Elastic Net, SVM, Random Forest).
87
A drawback of the standard cross-validation scheme is that the same cell line can be 88 in different cross-validation folds (but for different drug combinations), which could bias 89 the predictive performance. To test for this, we also performed leave-one-cell-line-out 90 cross-validation, in which all data associated with a given cell line were left out from the 91 training step of a given fold. Overall, we found that joint models were more predictive 92 than individual ones using leave-one-cell-line-out cross-validation too (Fig 2B) , ruling 93 out this bias. We also observed that the individual Random Forest models resulted in 94 negative predictive performance in this setting (Fig 2B) , whereas the predictive 95 performance was positive using regular cross-validation (Fig 2A) . This too can be 96 attributed to the aforementioned cross-validation artifact (S2 Text).
97
To determine whether the joint models were predictive for specific classes of drug,
98
we grouped the 119 drugs into 19 drug classes and checked whether the difference in 99 predictive performance between the individual or joint models was associated with any 100 of the drug classes. This showed that drug combinations containing IGFR inhibitors are 101 significantly better predicted using the joint model (Mann-Whitney U test,
102
FDR-corrected p = 0.047) (Fig 2C) . Furthermore, for drug combinations containing 103 DNA damaging agents (DDA), the joint model showed on average no increase in 104 predictive performance (Fig 2D, bottom panel) . Compared to the overall increase in 105 predictive performance between individual and joint models, this effect was significant 106 (Mann-Whitney U test, FDR-corrected p = 0.036) ( Figure 2D , top panel).
107
To further characterize the joint model predictive performance improvement, we 108 used a simulated dataset and assessed under which conditions joint models outperform 109 individual models using Random Forests. In this simulation, we created a data set of 110 similar size as the DREAM data and then varied the sample size or the number of 111 features (Methods). We found that simultaneously learning across drug combinations 112 was most beneficial in highly underdetermined cases, i.e. when the sample size was low 113 or the number of variables was high (Fig S1) . Interestingly, when the number of samples 114 was sufficiently high (e.g. n = 100), the individual and joint Random Forest models 115 achieved virtually identical predictive performance.
116
Altogether, our results show that, for most combinations, joint models obtain a In an initial attempt to identify biomarkers of synergy using the joint model, we first 124 computed the Random Forest's variable importance score (VI), referred to as the joint 125 model VI score (JVI) (Fig 3A) . Ranking the variables by their JVI, we identified 126 variables that had a large impact on the prediction of many different drug combinations. 127 We found that the monotherapy variables were the most important variables overall 128 (highest JVI scores in Fig 4) To identify biomarkers for a specific drug combination using the Joint Random Forest 143 model, we developed a Drug-combination-specific Variable Importance score (DVI)
144
( Fig 3A) . The DVI determines the contribution of each variable to the prediction in the 145 same way as the original Random Forest VI score, but only considers the samples from 146 one drug combination at a time ( Fig 3B) . To evaluate the DVI, we created a simulated 147 dataset in which we engineered a biomarker with two parameters: 1) e: the effect size of 148 the association of the biomarker with synergy; and 2) d: the number of drug 149 combinations for which this biomarker was engineered to be associated with synergy. As 150 expected, increasing either one of these enhances the ability of the DVI to identify the 151 biomarker ( Fig 5B) .
152
We then used the simulated dataset to compare the DVI to the Individual model
153
Variable Importance (IVI, Random Forest VI score on individual models). This showed 154 that the ability of the IVI to identify the engineered biomarker is correlated with the 155 effect size (e), but not with the number of drug combinations (d) ( Figure 5A ). This is 156 expected, since the Individual Random Forest models (underlying the IVI scores) do not 157 share information across different drug combinations. Hence, increasing d has no effect 158 on the model's ability to recover the biomarker. Interestingly, we found that biomarkers 159 with a sufficiently large effect size are identified by both the IVI and the DVI. We found 160 that the DVI is significantly better than the IVI at identifying the biomarker in 161 scenarios where e is small and d is high ( Figure 5C ).
162
These findings were reflected in the DREAM data. For example, ranking the 163 associations by their DVI, the highest-ranking molecular data variable was the 164 association of ATAD5 mutation status with synergy between IAP inhibitors and TNF 165 inhibitors ( Figure 5D ). As ATAD5, IAP and TNF are all part of the apoptosis pathway, 166 this illustrates that the DVI is able to identify interesting associations. Given the large 167 effect size, it is not surprising that this association is ranked high for this drug 168 combination by both the DVI (ranked #3) and the IVI (ranked #1 Drug combinations are of great interest in cancer care, as they can increase treatment 203 efficacy. However, without specific biomarkers, it is difficult to predict which drug 204 combinations will have a synergistic effect in a given patient. Most current approaches 205 for identifying biomarkers of single drug response fit a separate model for each drug.
206
We have shown that such an approach does not obtain good prediction performance for 207 predicting synergy in the DREAM data, likely due to the low sample size. To alleviate 208 this limitation, we used multi-task learning to leverage the information contained in 209 several drug combinations. Compared to previous work [9, 13, 14, 19] , our model has the 210 advantage that it is not a 'black-box method' and hence can identify biomarkers.
211
In our models, we found that monotherapy data are important for predicting synergy. 212 Recently, Gayvert et al. (2017) [7] have analyzed a similar drug synergy screen, in which 213 they report the same, but do not offer a rationale. We believe that the link between 214 monotherapy and synergy could be attributed to both biological and technical reasons. 215 A biological explanation may be that a small reduction in viability using monotherapy 216 can be evidence of target engagement by the drug, which is required for synergy. On the 217 other hand, the high variable importance of monotherapy can also be technical. When 218 one of the drugs is very potent (e.g. kills 80% of the cells by itself), the expectation is 219 that the combination will kill most cells even if the effect is only additive. Hence, 220 detecting the difference between synergy and additivity would become very difficult in 221 this scenario, as this difference may not exceed the noise level. We note that both 
225
Another interesting observation is that, on average, using a joint or individual which might also apply to synergy prediction.
230
An interesting extension of our method would be the inclusion of variables specific to
239
In summary, we have presented a method that circumvents the problem of low 240 sample sizes by combining information across drug combinations. In contrast to 241 previous work, our method allows for the identification of biomarkers. With the large 242 number of possible drug combinations, many future drug combination screens are likely 243 to be performed in a small number of cell lines. We believe that our approach can aid to 244 identify biomarkers specifically in such screens.
245
Methods
246
Individual and joint prediction models
247
Predictive models are typically trained per drug combination (Fig 1A) . We refer to 248 these models as 'individual models'. In this work, we propose a 'joint model', which is 249 simultaneously trained on data from all drug combinations (Fig 1B) . Such an approach 250 can be viewed as multi-task learning, where each drug combination represents a task.
251
The joint model takes an augmented matrix X drug combinations, none were used in this work).
261
These three categories are visualized in Fig S2 in purple, green and blue respectively.
262
The response vector y * was defined as the concatenation of the response values, such 263 that each sample corresponds to a cell line, drug combination pair. The resulting input 264 data X * can be fitted onto y * using standard machine learning algorithms. In this work, 265 we have compared three different algorithms:
266
• Elastic Net [20] , as implemented in the R package glmnet [6] , with α set to 0.5 267 and λ optimized in a nested cross-validation loop.
268
• SVM [3] with RBF kernels, as implemented in the Python package 
271
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• Random Forest [10] , as implemented in the Python package scikit-learn, using 272 default parameters.
273
We compared these joint models to 'individual models', which are trained per drug 274 combination and contain the same variables, except the drug combination indicator 275 variables (which are constant within a given drug combination). Predictive performance 276 was assessed using 2-fold cross-validation with the 'primary score' (a weighted average 277 of the correlation between the observed and predicted synergy scores) as described in 
where q is the number of drug combinations, n i the number of cell lines in drug Subsequently, we trained an individual and a joint Random Forest on these data.
298
We evaluated the predictive performance by generating a separate test set, using the 299 same characteristics as the ones used to create the training data. The performance was 300 measured using the 'primary score' described above.
301
To study the effect of sample size on the predictive performance, we varied the 302 sample size between 14, 25, 50 and 100. Likewise, to study the effect of the number of 303 variables, we varied the number of variables between 125, 250, 497 and 1000.
304
Variable importance measures
305
The basic idea of the permuted variable importance [2] is that a variable is considered 306 to be important if it has a positive effect on predictive performance. The importance of 307 a variable X j is evaluated by, for a given tree in the forest, calculating the prediction In this work, we used the permuted variable importance in two different ways
314
( Figure 3A ). We generated a simulated dataset as above (14 cell 
342
• 10 Individual Random Forest models, followed by IVI to rank the variables per 343 drug combination.
344
For each of the parametrizations (e and d), we determined:
345
• The median rank of the engineered association using a Joint Random Forest.
346
• The median rank of the engineered association using an Individual Random Forest. 347
• The significance of the difference between these two medians, using a Wilcoxon 348 signed-rank test.
349
When d = 1, we determine median rank of the engineered association using the 50 350 repeats. When d = 3, we use the ranks for the 50 repeats in each of the 3 drug 351 combinations in which the association was engineered, essentially yielding 150 repeats. 352 In general, for each parameterization we determine the median rank of the engineered 353 association using the 50d repeats.
354
We determined the significance of the difference between the individual and the joint 355 model as follows. For each repeat and for each parametrization of e and d, we 356 determined the median rank of the association across the d drug combinations in which 357 the association was engineered. For each parametrization of e and d, we then determined 358 the significance using a Wilcoxon signed-rank test (across the 50 repeats). The resulting 359 p-values were corrected for multiple testing using a Benjamini-Hochberg correction. In order to obtain a variable importance for each drug combination using the Joint Random Forest model, we propose the Drug-combination-specific Variable Importance (DVI). B: Illustration of the JVI and the DVI in a single decision tree from the random forest. For both variable importance scores, the importance is assessed by permuting the values of the given variable (a permuted variable is indicated by a horizontal arrow here) and then calculating for each sample (a sample is indicated by a box at the bottom of the tree) the difference between the permuted and unpermuted errors. In the given example, variable A is more important than variable B, as indicated by the higher difference in error (∆MSE) when permuting variable A. Associations using the IVI and the DVI. Associations using the Individual model Variable Importance (IVI) and the Drug-combination-specific Variable Importance (DVI) A&B: Heatmap showing the median rank of the engineered biomarker in the simulated dataset, stratified by effect size (e) and number of drug combinations for which the biomarker was engineered to be associated with synergy (d), using either (A) the IVI or (B) the DVI. C: Heatmap showing for which e (effect size) and which d (number of drug combinations for which the biomarker was engineered to be associated with synergy) the DVI is significantly better (indicated in pink) than the IVI at retrieving the association in a simulated dataset. Examples used in this paper from the DREAM data (associations with MYO15A and ATAD5 ) are indicated in this plot based on their effect size and the number of drug combinations in which we observe them. D: Synergy score for a combination of an IAPi and an TNFi, stratified by ATAD5 mutation status. 
